Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
HomeLetteratura (Page 2)
Archivio

Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a global health concern. Currently, some therapies and vaccines have gotten the FDA approval or emergency use authorization (EUA) for the management of coronavirus disease 2019 (COVID-19). According to the pathophysiology of the

J Clin Pharmacol 2021 Jan 28. Online ahead of print. /  Khani E, Khiali S, Entezari-Maleki T.

SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE21, and is a major antibody target. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences over 23 time points spanning 101 days.

Nature 2021 Feb 5. Online ahead of print. /  Kemp Sa, et al.

Objectives: The implementation of rapid diagnostic tests (RDTs) may enhance the efficiency of SARS-CoV-2 testing, as RDTs are widely accessible and easy to use. The aim of this study was to evaluate the performance of a diagnosis strategy based on a combination of antigen and IgM/IgG serological RDTs. Methods: Plasma and

J Med Virol 2021 Feb 8. Online ahead of print. /  Veyrenche N, et al.

La produzione di letteratura medico-scientifica è in aumento e l’emergenza sanitaria causata dalla pandemia di CoViD-19 ha determinato un’ulteriore crescita del numero di articoli pubblicati ogni anno sulle riviste internazionali. Orientarsi in questo oceano di informazioni è molto difficile: la valutazione critica della documentazione scientifica richiede tempo e specifiche competenze, non

Recenti Prog Med 2021;112(1):22-24. /  De Fiore R.

Purpose: Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non-small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation or gene amplification. Materials and methods: Patients who participated in the screening of a phase II study

Cancer Res Treat 2021 Jan 29. doi: 10.4143/crt.2020.1331. /  Choi et al.

Objective: The purpose of this study was to identify trends in oncology care that allow one to forecast workforce supply and demand, the training and skills needed by the oncology pharmacist for the likely future of oncology care. Methods: Interviews were conducted with experienced oncology pharmacists in leadership roles at 20

Journal of Oncology Pharmacy Practice 2021;27(1):5-13. /  Ignoffo RJ, Knapp KK, Seung A, et al.

Background: In advanced clinical decision support systems, patient characteristics and laboratory values are included in the algorithms that generate alerts. These alerts have a higher specificity than basic medication surveillance alerts. The alerts of advanced clinical decision support systems can be shown directly to the prescriber during order entry, without

Int J Clin Pharm 2021; 43: 137–143. /  Becker ML, Baypinar F, Pereboom M, et al.

Chimeric antigen receptor (CAR) T cell therapy improves the remission rate of refractory/relapsed B-acute lymphoblastic leukemia (R/R B-ALL) patients, but the relapse rate remains high. Recent studies suggest patients who underwent post-chimeric antigen receptor T cell therapy hematopoietic stem cell transplantation (post- HSCT) would achieve durable remission and better survival, but

Ann Hemato 2021 Feb 15. Epub ahead of print. /  Hu L, Charwudzi A, Li Q, et al.

Background: Inclusion of productivity losses and gains in cost-effectiveness analyses for drugs is recommended by pharmacoeconomic guidelines in some countries and is considered optional in others. Often guidelines recommend analysis based on the payer perspective, but suggest that a supplemental analysis based on the societal perspective may be submitted that

PharmacoEconomics 2021; 39: 81–97. /  Yuasa A, Yonemoto, N, LoPresti, M. et al.

Background: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. Methods: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients

N Engl J Med 2020; 383:1813-1826 /  Beigel JH, Tomashek KM, Dodd LE, et al.